Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Dualyx","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dualyx Raises 40 Million To Progress Treg Therapies For Autoimmune Diseases Into The Clinic","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Dualyx

    Menu

    Dualyx

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Dualyx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Belgium
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dualyx Raises 40 Million To Progress Treg Therapies For Autoimmune Diseases Into The Clinic

              Details:

              The use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting the highly attractive TNF receptor 2 (TNFR2) and widely regarded as a master control switch in immune modulation, as well as its pipeline of Treg candidates.

              Lead Product(s): DT-001

              Therapeutic Area: Immunology Product Name: DT-001

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Fountain Healthcare Partners

              Deal Size: $44.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing May 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY